These analyses confirmed that the protective association of high STAT5B expression was particularly strong in hematologic malignancies (lnHR = −0.6988; 95% CI: −0.9780 to −0.4197; p < 0.0001) and lung cancers (lnHR = −0.5170; 95% CI: −0.8710 to −0.1630; p = 0.0042) (Figure 5). Here, STAT5B is linked to hematologic disorder.